Streetbeat News

Stock Prices

MKTX

Rosenblatt analyst Andrew Bond maintains a 'Sell' rating on MarketAxess Holdings (NASDAQ:MKTX) and has lowered the price target from $254 to $234.

Portfolio Pulse from richadhand@benzinga.com

July 07, 2023 | 11:17 am

BIIB

Biogen's shares resumed trading and rose 2.5% following the FDA's approval of its Alzheimer's drug, Leqembi, on Thursday.

Portfolio Pulse from Charles Gross

July 07, 2023 | 11:16 am

KALV

KalVista Pharma (NASDAQ:KALV) reported its Q4 earnings, beating estimated earnings by 18.09% with an EPS of $-0.77 versus an estimate of $-0.94. However, revenue was down $0 from the same period last year. Last quarter, the company beat on EPS by $0.23, which was followed by a 5.31% drop in the share price the next day.

Portfolio Pulse from Benzinga Insights

July 07, 2023 | 11:10 am

BIIB

Trading of Biogen shares has resumed.

Portfolio Pulse from Charles Gross

July 07, 2023 | 11:10 am

BRTX

BioRestorative Therapies' drug candidate BRTX-100 has passed safety tests and is moving ahead with Phase 2 of its development. This is a significant milestone for the company and could potentially impact its stock price.

Portfolio Pulse from Benzinga Newsdesk

July 07, 2023 | 11:08 am

AAON

AAON has announced a 3-for-2 stock split, which will be paid in the form of a stock dividend.

Portfolio Pulse from Benzinga Newsdesk

July 07, 2023 | 11:05 am

LLY

NVO

Novo Nordisk has filed lawsuits against TruLife Pharmacy, Brooksville Pharmaceuticals, and WellHealth Inc, accusing them of illegally selling products containing semaglutide, an active ingredient in Novo Nordisk's weight loss and diabetes drugs. The company argues that these actions create an unfair competitive advantage and jeopardize patient safety. The global weight-loss therapies market is expected to reach $100 billion in the next decade, with Novo Nordisk and Eli Lilly as the primary beneficiaries.

Portfolio Pulse from Vandana Singh

July 07, 2023 | 11:03 am

BIIB

Trading of Biogen shares is set to resume at 7:10 AM ET.

Portfolio Pulse from Charles Gross

July 07, 2023 | 10:53 am

BIIB

COST

LEVI

QQQ

SPY

Stock futures dipped slightly on Friday as traders awaited the June non-farm payrolls report. Thursday's trading saw stocks close lower due to data suggesting a tight labor market and speculation of a rate hike at the upcoming Federal Reserve meeting. The SPDR S&P 500 ETF Trust (NYSE:SPY) and the Invesco QQQ ETF (NASDAQ:QQQ) both fell in premarket trading. Levi Strauss & Co. (NYSE:LEVI), Biogen, Inc. (NYSE:BIIB), and Costco Wholesale Corp. (NASDAQ:COST) are in focus due to recent developments.

Portfolio Pulse from Shanthi Rexaline

July 07, 2023 | 10:52 am

BTAI

LEVI

LXRX

RIOT

SENS

VRNS

Several US stocks are trading lower in the pre-market session. Levi Strauss & Co. (LEVI) shares dipped 8.2% despite reporting upbeat Q2 earnings, as the company lowered its annual profit outlook. BioXcel Therapeutics (BTAI) shares fell 7.4% following the release of topline results for a Phase 3 trial of BXCL501 for Alzheimer's disease-related agitation. Senseonics Holdings (SENS) shares dropped 5.4% after reporting equity grants to employees. Varonis Systems (VRNS) shares declined 4.8%, Lexicon Pharmaceuticals (LXRX) shares fell 3.2%, and Riot Platforms (RIOT) shares slipped 2.5% after issuing production and operations updates.

Portfolio Pulse from Lisa Levin

July 07, 2023 | 10:48 am